TABLE 2.
Cox regression for overall survival of patients with limited stage.
| Univariate | Multivariate (1) | Multivariate (2) | Multivariate (3) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p‐value | HR | 95% CI | p‐value | HR | 95% CI | p‐value | HR | 95% CI | p‐value | |
| Age | 1.062 | 1.028–1.096 | < 0.001 | 1.047 | 1.004–1.092 | 0.034 | 1.051 | 1.008–1.097 | 0.021 | 1.048 | 1.007–1.091 | 0.021 |
| Sex | ||||||||||||
| Male | Ref. | |||||||||||
| Female | 0.582 | 0.273–1.242 | 0.162 | |||||||||
| ECOG PS | ||||||||||||
| 0–1 | Ref. | Ref. | Ref. | Ref. | ||||||||
| 2–3 | 4.587 | 2.291–9.185 | < 0.001 | 3.280 | 1.560–6.895 | 0.002 | 2.904 | 1.409–5.983 | 0.004 | 2.482 | 1.176–5.236 | 0.017 |
| Chemotherapy regimen | ||||||||||||
| Etoposide/carboplatin | Ref. | Ref. | Ref. | Ref. | ||||||||
| Etoposide/cisplatin | 0.464 | 0.270–0.799 | 0.006 | 0.853 | 0.414–1.760 | 0.667 | 1.148 | 0.572–2.304 | 0.697 | 0.966 | 0.503–1.853 | 0.917 |
| Dose reduction since the first cycle | ||||||||||||
| No | Ref. | Ref. | Ref. | Ref. | ||||||||
| Yes | 2.201 | 1.175–4.120 | 0.014 | 1.022 | 0.495–2.112 | 0.952 | 0.972 | 0.468–2.017 | 0.939 | 1.152 | 0.561–2.367 | 0.699 |
| Lipocalin‐2 | ||||||||||||
| Low | Ref. | Ref. | ||||||||||
| High | 1.747 | 1.034–2.954 | 0.037 | 1.193 | 0.630–2.258 | 0.588 | ||||||
| Lipocalin‐2 + PMI | 2.369 | 1.513–3.709 | < 0.001 | 2.013 | 1.210–3.351 | 0.007 | ||||||
| Lipocalin‐2 + NLR | 1.894 | 1.297–2.765 | 0.001 | 1.708 | 1.081–2.701 | 0.022 | ||||||
Note: Since only one factor among lipocalin‐2, lipocalin‐2 + PMI, and lipocalin‐2 + NLR should be selected as a variable in each analysis, used gray shading to indicate ‘blank’.
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NLR, neutrophil‐lymphocyte ratio; PMI, pectoralis muscle index.